Fierce Pharma
SEPTEMBER 20, 2024
The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program. | Bristol Myers Squibb is laying off an additional 79 staffers in Lawrenceville, New Jersey. The cuts will be effective between Dec. 12 and May 30 of next year and are part of BMS's $1.5 billion cost reduction program.
MedCity News
SEPTEMBER 20, 2024
Many are already experimenting with AI in narrow settings. But in order to expand deployment, it’s important to understand the most practical AI opportunities with the greatest ROI. Here are four high-impact opportunities that can boost staff efficiency and improve the patient experience. The post From Charting to Patient Intake: The 4 Biggest Opportunities for AI in Healthcare appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 20, 2024
Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of AstraZeneca’s Tagrisso in non-small cell lung cancer (NSCLC). | Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of AstraZeneca’s Tagrisso in non-small cell lung cancer (NSCLC).
MedCity News
SEPTEMBER 20, 2024
We need to continue investing in research for early stage, localized prostate cancer, develop treatments that balance efficacy with quality-of-life considerations, ensure diverse representation in clinical trials, and listen to patients and incorporate their perspectives into treatment development and decision-making. The post Prostate Cancer Management – We Need Better Options for Early-Stage Disease appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 20, 2024
Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been left in the cold once again. | Europe’s Committee for Medicinal Products for Human Use has confirmed its negative stance on pegcetacoplan in geographic atrophy, an advanced form of age-related macular degeneration that can lead to blindness.
MedCity News
SEPTEMBER 20, 2024
Meditech is integrating Suki’s AI assistant into more than a dozen rural health systems, including St. Mary’s Healthcare in New York and Decatur County Memorial Hospital in Indiana. The post When It Comes to AI, Rural Doctors Have FOMO — Meditech & Suki Are Teaming Up to Address This appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 20, 2024
Active investors chose Healthy Young Minds as the Pitch Perfect winner at the INVEST Digital Health Conference in Dallas. See how the company’s CEO accepted the award. The post Video: INVEST Digital Health Pitch Perfect Winner Accepting Award appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 20, 2024
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. | Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday.
pharmaphorum
SEPTEMBER 20, 2024
Astellas is ready to launch its first digital health product in the US, called Digitiva, which provides at-home monitoring of people with heart failure
Fierce Pharma
SEPTEMBER 20, 2024
AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on AstraZeneca's influenza vaccine FluMist for self-administration by adults up to 49 years old and for administration by a parent or caregiver in kids between the ages of 2 and 17. With the green light, FluMist is now the only flu vaccine in the U.S. patients can give to themselves.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
SEPTEMBER 20, 2024
J&J's target of $5bn in sales for Rybrevant has moved a step closer, after an FDA approval for second-line treatment of EGFR+ NSCLC
Fierce Pharma
SEPTEMBER 20, 2024
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations aliu Fri, 09/20/2024 - 09:21
MedCity News
SEPTEMBER 20, 2024
In two letters, U.S. representatives and senators called for an extension of the enhanced premium tax credits, which are set to expire in 2025 and have lowered costs for those purchasing coverage on the marketplace. The post 195 Congress Members Call for Extension of Enhanced Premium Tax Credits appeared first on MedCity News.
PharmaTech
SEPTEMBER 20, 2024
Hayley Crowe, executive vice-president and general manager Global Life Sciences at Ecolab discussed at BIO 2024 how technology innovations have enhanced downstream bioprocessing.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
MedCity News
SEPTEMBER 20, 2024
Zevra Therapeutics drug Miplyffa is now FDA approved for Niemann-Pick disease type C, a lysosomal storage disorder. The affirmative regulatory decision took into account additional clinical data generated since the FDA turned down a submission for the drug in 2021. The post FDA Approval Makes a Zevra Drug the First Therapy for Rare and Fatal Metabolic Disease appeared first on MedCity News.
PharmaTech
SEPTEMBER 20, 2024
The announcement of the pairing comes several months after Adare Pharma Solutions said it would upgrade several of its facilities, including in Milan, Italy, where the 3D printing operations will be located.
Pharmaceutical Commerce
SEPTEMBER 20, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, discusses why mitigating the impact of rising costs is imperative, while explaining the benefit of advanced analytics tools.
PharmaTech
SEPTEMBER 20, 2024
In this video, hear Albert McEvoy, Senior Director of NORAM Logistics, talk about how Marken is preparing its pharma supply chains for a new age of healthcare by optimizing drug development and delivery through cutting-edge tech, strategic partnerships, and contingency plans ― a future where patients anywhere in the world have access to essential medicines.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmExec
SEPTEMBER 20, 2024
Rybrevant is the first targeted second-line regimen to significantly reduce the risk of disease progression by more than 50% in patients with locally advanced or metastatic EGFR mutated non-small cell lung cancer, according to Johnson & Johnson.
PharmaTech
SEPTEMBER 20, 2024
The collaboration is designed to combine NanoVation Therapeutics’ lipid nanoparticle technology for RNA delivery to cells outside the liver with Novo Nordisk’s knowledge of cardiometabolic and rare disease R&D.
PM360
SEPTEMBER 20, 2024
LONDON, September 20, 2024 – The Creative Floor Healthcare Awards, celebrated the world’s best health and wellness creative work, agency talent and clients yesterday at its 11th year extravaganza in London. Klick Health won the Most Awarded Agency, IPG Health won the Most Awarded Network and Tim Hawkey from Area 23 picked up the inaugural Hall of Legends crimson-blood award.
PharmaVoice
SEPTEMBER 20, 2024
Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.
PharmaTech
SEPTEMBER 20, 2024
Vectura’s expertise in the field includes formulation and device development for dry powder inhalers and pressurized metered dose inhalers, among other products and services.
PharmaVoice
SEPTEMBER 20, 2024
A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.
Pharmaceutical Technology
SEPTEMBER 20, 2024
In this issue: Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing vaccines for Disease X, and more.
PharmExec
SEPTEMBER 20, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
SEPTEMBER 20, 2024
The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.
PharmExec
SEPTEMBER 20, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
SEPTEMBER 20, 2024
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s Wegovy label.
PharmExec
SEPTEMBER 20, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
262 
Let's personalize your content